Corbus enrols first patient in pivotal-intent TEMPO-1 head-and-neck trial for Nectin-4 ADC
The US biotech's updated investor deck shows its lead antibody-drug conjugate moving into a late-stage study, with about $115M in cash and investments backing it and an obesity asset.
Corbus Pharmaceuticals has begun treating patients in TEMPO-1, the study intended to support registration of its Nectin-4-directed antibody-drug conjugate, sutantatug envedotin (SUTA-E), in oropharyngeal squamous cell carcinoma (OPSCC). The company says dosing began in September 2026. The news comes from a refreshed corporate presentation with figures dated 30 September 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Corbus Pharmaceuticals Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.